Lung Cancer

The FDA cleared an investigational new drug application for FT536, a chimeric antigen receptor natural killer cell therapy designed to treat adults with certain relapsed or refractory solid tumors.

Researchers reported that every 5-g increase in daily fiber intake correlated with a nearly 30% lower risk for disease progression or death among patients with melanoma who were treated with immune checkpoint inhibitors.

An increasing percentage of lung cancer cases are being diagnosed at an earlier stage, according to a new report from American Cancer Society.

Pembrolizumab extended DFS compared with placebo as adjuvant treatment for patients with stage IB to stage IIIA non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The FDA granted breakthrough therapy designation to telisotuzumab vedotin for treatment of certain patients with non-small cell lung cancer.

The FDA granted breakthrough therapy designation to CLN-081 for treatment of certain patients with non-small cell lung cancer.

Cutaneous adverse events appeared largely reversible and rarely led to therapy discontinuation among patients with metastatic melanoma treated with combination checkpoint inhibitors, according to a study in Cancer.

Survivors of head and neck cancer appeared at increased risk for a second primary lung cancer, according to results of an ad hoc secondary analysis of a randomized trial published in JAMA Otolaryngology-Head & Neck Surgery.

Quitting smoking at or around time of diagnosis conferred a significant survival benefit for patients with lung cancer, according to results of a meta-analysis published in Journal of Thoracic Oncology.

The FDA granted breakthrough therapy designation to patritumab deruxtecan for treatment of certain patients with non-small cell lung cancer.